Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bela Merkely

Showing results (241-250 of 296) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
Lancet (London, England)|November 9, 2015
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trialA Michael Lincoff, Roxana Mehran, Thomas J Povsic, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
European Journal of Preventive Cardiology|November 6, 2016
Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECELluís Mont, Antonio Pelliccia, Sanjay Sharma, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
JAMA Cardiology|May 19, 2021
Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve ReplacementUri Landes, Guy Witberg, Janarthanan Sathananthan, et al.
Pageof 30

Showing results (241-250 of 296) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
Lancet (London, England)|November 9, 2015
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trialA Michael Lincoff, Roxana Mehran, Thomas J Povsic, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
European Journal of Preventive Cardiology|November 6, 2016
Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECELluís Mont, Antonio Pelliccia, Sanjay Sharma, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
JAMA Cardiology|May 19, 2021
Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve ReplacementUri Landes, Guy Witberg, Janarthanan Sathananthan, et al.
Pageof 30